Trump Media Announces Release of Truth+ Streaming on Roku

Truth+ streaming app now available for Roku TV sets

SARASOTA, Fla., March 19, 2025 (GLOBE NEWSWIRE) — Trump Media and Technology Group Corp. (Nasdaq: DJT) (“TMTG” or the “Company”), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, announced today that it has successfully launched an app for Roku TVs to access the Truth+ streaming platform.

Now available in the Roku Channel Store, Truth+ offers family-friendly TV programming for patriotic Americans who want an alternative to woke entertainment corporations and biased news channels.

Truth+ provides reliable news broadcasts, entertainment, faith-based content, weather, documentaries, children’s content, and more, featuring both live TV channels and Video on Demand (VOD). The Roku app will initially provide access to live TV channels, with VOD content to be added in the near future.

Currently available on iOS devices, Android devices, Apple TVs, Android TVs, Amazon Fire TVs, and on the Web, Truth+ offers features including live TV rewind with visual thumbnails, catch-up TV for up to seven days, network DVR, and a Spanish language interface option.

Roku TV owners can now download the Truth+ app directly to their TV sets from the Roku Channel Store, then sign in by using their mobile phones to scan a QR code from their TV sets or by using a passcode. Users without a Truth Social account can create one during the sign in process.

“We’re bringing Truth+ to Roku and planning to release more TV apps soon,” said TMTG CEO and Chairman Devin Nunes. “Truth+ is the singular option for non-woke TV and movies, as well as a great alternative to discredited legacy news channels that have squandered the trust of the American people.”

In the near future, TMTG plans to introduce Truth+ native apps for additional connected TV platforms including Samsung and LG.

TMTG anticipates that, as the rollout progresses, the Company will continue to stress and beta test the streaming technology while collecting input from users and to announce when testing is finished and the rollout is complete.

TMTG’s ultra-fast streaming technology is powered through its custom-designed, multi-site Content Delivery Network (CDN) using the Company’s own servers, routers, and software stack, created with the goal of rendering the service uncancellable by Big Tech.

Cautionary Statement About Forward-Looking Statements

This press release includes forward-looking statements regarding, among other things, the plans, strategies, and prospects, both business and financial, of TMTG. We have based these forward-looking statements on our current expectations and projections about future events, including potential merger & acquisition activity, the rollout of products and features, the future plans, timing and potential success of the streaming services and the launch and success of our financial services and FinTech platform. Although we believe that our plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions, or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. These statements may be preceded by, followed by, or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “soon,” “goal,” “intends,” or similar expressions. Forward-looking statements are not guarantees of future performance, and involve risks, uncertainties and assumptions that may cause our actual results to differ materially from the expectations that we describe in our forward-looking statements. There may be events in the future that we are not accurately able to predict, or over which we have no control.

About TMTG

The mission of TMTG is to end Big Tech’s assault on free speech by opening up the Internet and giving people their voices back. TMTG operates Truth Social, a social media platform established as a safe harbor for free expression amid increasingly harsh censorship by Big Tech corporations, as well as Truth+, a TV streaming platform focusing on family-friendly live TV channels and on-demand content. TMTG is also launching Truth.Fi, a financial services and FinTech brand incorporating America First investment vehicles.

Investor Relations Contact

Shannon Devine (MZ Group | Managing Director – MZ North America)
Email: [email protected]

Media Contact

[email protected]



Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

PR Newswire

–    Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning

–    Clinical proof of concept data expected in 2H:2025 from Actimab-A combination with blockbuster immunotherapies KEYTRUDA® and OPDIVO® in solid tumor indications

–    Actimab-A expanded into frontline AML in triplet combination with Venetoclax and ASTX-727, Taiho Oncology’s hypomethylating agent, under NCI CRADA with initial clinical data expected by year-end 2025

–    Planned pivotal Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory AML patients further supported by recent publication of results in peer-reviewed journal Leukemia reporting 18.4 median overall survival

–    Iomab-ACT commercial CAR-T trial to initiate patient enrollment with clinical proof of concept data expected in 2H:2025; Iomab-ACT sickle cell disease trial expected to initiate in 1H:2025

–       Call Scheduled for 8:00 AM ET on Tuesday, March 25, 2025


NEW YORK
, March 19, 2025 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that it will host a KOL call that will feature Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin and principal investigator of the Actimab-A + CLAG-M combination trial in patients with relapsed/refractory acute myeloid leukemia (r/r AML). Dr. Atallah will discuss Actimab-A clinical results to date including recently published long-term survival outcomes and the planned pivotal Phase 2/3 clinical trial in r/r AML and trials to be conducted under Actinium’s cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI). In addition, Actinium will provide a pipeline update to highlight 3 separate potential multi-billion-dollar blockbuster market opportunities for its targeted radiotherapies including the following:

  • Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including AML and myelodysplastic syndromes (MDS) across multiple treatment settings
  • Actimab-A as a pan solid tumor therapy in combination with PD-1 inhibitors including KEYTRUDA and OPDIVO by depleting myeloid derived suppressor cells (MDSCs)
  • Iomab-ACT as a universal targeted conditioning agent to increase patients access to cell & gene therapies and improve patient outcomes

To register for the KOL Call & Pipeline Update please use the following link:

https://lifescievents.com/event/actinium-2/

Sandesh Seth, Actinium’s Chairman and CEO, said, “We have made significant progress across our pipeline in the first quarter of 2025 achieving several important milestones. We are excited to highlight the large multi-billion-dollar market opportunities for Actimab-A in myeloid malignancies and now solid tumors, as well as cell and gene therapy conditioning with Iomab-ACT. With cash runway into 2027, we are in an excellent position to advance our programs, and we are excited to deliver validating data in the second half of 2025.”

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. Iomab-ACT, Actinium’s next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for in the U.S. In addition, the company’s R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: https://www.actiniumpharma.com/

Forward-Looking Statements

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investors:

[email protected] 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-host-investor-kol-call-with-dr-ehab-atallah-of-the-medical-college-of-wisconsin-and-provide-a-pipeline-update-highlighting-revamped-clinical-programs-and-expanded-market-opportunities-for-actimab-a-and-302405753.html

SOURCE Actinium Pharmaceuticals, Inc.

BGM Acquires YX to Strengthen AI Strategy for Its Intelligent Platform

PR Newswire


CHENGDU, China
, March 19, 2025 /PRNewswire/ — BGM Group Ltd. (the “Company” or BGM) (NASDAQ: BGM) today announced that it has signed a definitive agreement with the existing shareholders of YX Management Company Ltd. (“YX”), a smart mobility technology company. Under the agreement, BGM will acquire 100% of the equity interests of YX by issuing 47.5 million class A ordinary shares to its existing shareholders, valuing YX at US$95.0 million. This acquisition is based on the exceptional expertise and experience of the YX team in scalable operations, digital infrastructure development, and technology commercialization. The integration of this team will accelerate the AI-driven strategic upgrade of BGM’s intelligent platform, DuXiaoBao, injecting new momentum into the Company’s future growth. The transaction is expected to be completed by June 2025. As a result, YX’s existing shareholders will collectively hold approximately 32.8% of BGM’s total outstanding and issued ordinary shares and approximately 2.2% of its voting power.

The YX team comprises proven executives and technology experts from China’s leading internet companies, including Alibaba and Didi. They bring extensive experience in building and optimizing large-scale platforms. Its core members have played pivotal roles in major projects such as Taobao Mobile, Fliggy Travel, Didi’s ride-hailing services, and China’s national health code system, leading initiatives in large-scale user system architecture, digital transformation of complex business processes, and AI-driven commercialization. The team not only possesses deep expertise in scalable operations and complex system architecture but also extensive experience in public-private partnerships, cross-sector resource integration, and AI applications. Their addition will bring proven business model optimization, strong industry collaboration networks, and forward-looking technology commercialization strategies, further advancing the technological evolution and business expansion of DuXiaoBao.

Mr. Chen Xin, CEO of BGM, commented: “The integration of the YX team with DuXiaoBao will create a ‘multiplier effect’ through deep industry breakthroughs, digital technology reinvention, and ecosystem synergy. Their expertise in large-scale platform development, AI commercialization, and industry collaboration will accelerate the deployment of AI technologies and drive the transformation of our core business towards AI Agents. This will further strengthen BGM’s leadership in intelligent and digital technology innovation. Their operational experience, commercially viable strategies, and resource synergy will establish AI as a powerful engine for the Company’s value growth, ensuring long-term and sustainable returns.”

About BGM Group Ltd

BGM Group Ltd. has a strategic focus on the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals.

In terms of AI application implementation, the group relies on big data mining and AI Agent technology, and utilizes the two platforms of Du Xiao Bao and Bao Wang to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. Its services cover multiple key scenarios such as sales and marketing, underwriting assessment, claims processing, and customer service. The group is capable of analyzing consumer data, building consumer profiles, accurately predicting insurance needs, and providing highly customized services for consumers.

In the field of biopharmaceuticals, the group’s biopharmaceutical division mainly produces oxytetracycline API, crude heparin sodium, and licorice preparations, which are widely supplied to the global animal husbandry, pharmaceutical, and drug retail markets. The group deeply integrates AI-assisted decision-making into every link of production and manufacturing, achieving supply chain optimization, process efficiency improvement, and market trend prediction. This provides scientific decision-making basis for the management and offers high-quality products and precise services for consumers.

Forward-looking Statements

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Cision View original content:https://www.prnewswire.com/news-releases/bgm-acquires-yx-to-strengthen-ai-strategy-for-its-intelligent-platform-302405812.html

SOURCE BGM Group Ltd

Cheetah Mobile To Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 26, 2025

PR Newswire


BEIJING
, March 19, 2025 /PRNewswire/ — Cheetah Mobile Inc. (“Cheetah Mobile” or the “Company”) (NYSE: CMCM), a China-based IT company, today announced that it will report its financial results for the fourth quarter and fiscal year 2024 before the U.S. market opens on Wednesday, March 26, 2025. 

The earnings release will be available on the Company’s investor relations website at http://ir.cmcm.com.

Cheetah Mobile’s management will hold an earnings conference call at 7:00 AM on Wednesday, March 26, 2025, U.S. Eastern Time (7:00 PM on Wednesday, March 26, 2025, Beijing Time/Hong Kong Time). 

Participants may access the call by dialing the following numbers:


Main Line: 

International: 1-412-317-6061
United States Toll Free: 1-888-317-6003
Mainland China Toll Free: 4001-206115
Hong Kong Toll Free: 800-963976
Conference ID: 5690589


English Translation: 

International: 1-412-317-6061
United States Toll Free: 1-888-317-6003
Mainland China Toll Free: 4001-206115
Hong Kong Toll Free: 800-963976
Conference ID: 0936457

The replay of the conference call will be accessible through April 2, 2025 by dialing the following numbers:


Main Line: 

International: 1-412-317-0088     
United States Toll Free: +1-877-344-7529
Access Code: 3807372


English Translation: 

International: 1-412-317-0088
United States Toll Free: 1-877-344-7529
Access Code: 8387373

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at http://ir.cmcm.com.


About Cheetah Mobile Inc.

Cheetah Mobile is a China-based IT company with a commitment to AI innovation. It has attracted hundreds of millions of users through an array of internet products and services on PCs and mobile devices. At the same time, it actively engages in the independent research and development of its AI technologies, including LLM technologies. Cheetah Mobile provides advertising services to advertisers worldwide, value-added services including the sale of premium membership to its users, multi-cloud management platform to companies globally, as well as service robots to international clients. Cheetah Mobile is also committed to leveraging its cutting-edge AI technologies, including LLM technologies, to empower its products and make the world smarter. It has been listed on the New York Stock Exchange since May 2014.

For investor inquiries, please contact:
Helen Jing Zhu
Cheetah Mobile Inc.
Tel: +86 10 6292 7779
Email: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/cheetah-mobile-to-report-fourth-quarter-and-fiscal-year-2024-financial-results-on-march-26-2025-302405641.html

SOURCE Cheetah Mobile

Inspira Technologies’ Innovative Life-Support System to be Showcased at AmSECT 63rd International Conference 2025 in San Diego

PR Newswire

Leading perfusion professionals to experience Inspira’s FDA-cleared cardiopulmonary bypass INSPIRA™ ART100 technology at premier industry event

RA’ANANA, Israel, March 19, 2025 /PRNewswire/ — Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira,” “Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.S. Food and Drug Administration-cleared life-support system, the INSPIRA™ ART100, will be showcased at the American Society of Extracorporeal Technology (AmSECT) 63rd International Conference, taking place March 19-23, 2025, at the Loews Coronado Bay Resort in San Diego, California, by their distributor Glo-Med Networks Inc (“Glo-Med”).

Inspira_Technologies_Logo

Conference attendees will have the opportunity to explore Inspira’s cutting-edge cardiopulmonary bypass technology at Glo-Med’s booth. The INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024 for use in cardiopulmonary bypass procedures, represents an advancement in extracorporeal circulation technology.

“The AmSECT International Conference brings together leading perfusion professionals, providing an ideal platform to showcase our INSPIRA ART100 system,” said Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies. “This event offers an excellent opportunity to further expose our innovative technology to the perfusion community. We look forward to connecting with industry experts and demonstrating how our solutions can support medical professionals.”

Visitors interested in scheduling a personal meeting are welcome to contact Mr. Levi Perryman at [email protected] or visit Booth number 4.

About AmSECT 63rd International Conference

The American Society of ExtraCorporeal Technology (AmSECT) International Conference is the premier global event for perfusion professionals, focusing on advancements in extracorporeal circulation, patient care, and perfusion education. The event will feature the latest medical technologies, research, and discussions shaping the future of perfusion.

About Inspira Technologies

Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company’s flagship INSPIRA ART500 system aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in the U.S. and for Cardiopulmonary Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company’s HYLA blood sensor technology is designed to provide continuous, real-time blood monitoring without the need for blood draws. The Company’s pipeline products, including the INSPIRA ART500 (Gen 2), INSPIRA Cardi-ART, and HYLA blood sensor, are currently in development and have not yet received regulatory approval.

For more information, visit: https://inspira-technologies.com

Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

Capital Markets & Investor Contact
Arx | Capital Markets Advisors
North American Equities Desk
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/inspira-technologies-innovative-life-support-system-to-be-showcased-at-amsect-63rd-international-conference-2025-in-san-diego-302405781.html

SOURCE Inspira Technologies

Sun Life Executive Vice President and CFO Tim Deacon to speak at National Bank Financial Markets’ 23rd Annual Financial Services Conference

PR Newswire


TORONTO
, March 19, 2025 /PRNewswire/ – Tim Deacon, Executive Vice President & Chief Financial Officer, Sun Life, will participate in a fireside chat at the National Bank Financial Markets’ 23rd Annual Financial Services Conference.

Date:      March 26, 2025
Time:     11:30 a.m. ET 

The webcast replay will be available after the event at: https://www.sunlife.com/en/investors/presentations-and-events/past-events/

About Sun Life
Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of December 31, 2024, Sun Life had total assets under management of $1.54 trillion. For more information, please visit sunlife.com

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Note to editors: All figures in Canadian dollars

To contact Sun Life media relations, please email 

[email protected]

To contact Sun Life investor relations, please email 

[email protected]
 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sun-life-executive-vice-president-and-cfo-tim-deacon-to-speak-at-national-bank-financial-markets-23rd-annual-financial-services-conference-302405132.html

SOURCE Sun Life Financial Inc.

Verizon named a Leader in Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide

  • Recognition as a Leader is based on a combination of “Ability to Execute” and “Completeness of Vision.”
  • According to the report, “Leaders invest in the future of IoT that includes a continuum of value from IoT edge devices to IoT platforms and related analytics. Leaders perform skillfully and often exceed expectations. They have a clear vision of the market’s direction and develop competencies to maintain their leadership. Leaders engage customers and provide value across multiple geographies. They shape the market, rather than follow it, and they often set the benchmark for market growth.”
  • The recognition follows Verizon’s earlier recognition as a 2024 Gartner® Peer Insights™ Customers’ Choice for IoT, reflecting ratings from customers and end-users of IoT services.

NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) — Verizon announced today that it has been recognized as a Leader in the Gartner Magic Quadrant for Managed IoT Connectivity Services, Worldwide. Recognition as a Leader is based on “Completeness of Vision” and “Ability to Execute” for managed IoT services.

“We feel that this recognition of Verizon’s managed IoT connectivity services is a testament to the strength and completeness of our end-to-end IoT offering for customers of different industries, geographies and sizes,” said Daniel Lawson, SVP, Global Solutions and IoT, Verizon Business. “Our IoT connectivity offering — especially when integrated with other Verizon solutions and platforms like private 4G/5G, fixed wireless access, edge computing, and Sensor Insights — can help customers with data-driven automation in near-real time, asset tracking and monitoring, cybersecurity, quality control, and more. As we continue to strengthen our global IoT offerings and platforms, we look forward to further proliferating capabilities like these with business customers in the U.S. and abroad.”

In June of 2024, Verizon was named as a 2024 Gartner® Peer Insights™ Customers’ Choice for IoT, reflecting feedback from Verizon customers and end users of its IoT services. Customers’ Choice vendors meet or exceed both the market average Overall Experience and the market average User Interest and Adoption.

Verizon was also recently named a Leader in the first-ever Gartner Magic Quadrant™ for 4G and 5G Private Mobile Network Services.

Magic Quadrant Market Definition for IoT Connectivity Services

Gartner defines managed IoT connectivity services as “a market that enables secured connectivity, data collection, analysis, and additional decision services. These services provide businesses with the ability to monitor, manage and control (manually and through automation) assets associated with business processes. This includes connected consumer, commercial, or industrial products.”

According to the report, “Leaders invest in the future of IoT that includes a continuum of value from IoT edge devices to IoT platforms and related analytics. Leaders perform skillfully and often exceed expectations. They have a clear vision of the market’s direction and develop competencies to maintain their leadership. Leaders engage customers and provide value across multiple geographies. They shape the market, rather than follow it, and they often set the benchmark for market growth.”

Evaluation Criteria

For Ability to Execute, “Gartner evaluates vendors on the quality and efficacy of the processes, systems, methods or procedures that enable IT provider performance to be competitive, efficient and effective, and to positively impact revenue, retention and reputation within Gartner’s view of the market,” according to Gartner.

Gartner puts “high” weighting on the following for Ability to Execute: Customer Experience, Product or Service, Sales Execution/Pricing, and Operations. “Medium” weighting is placed on Market Responsiveness/Record and Marketing Execution.

For Completeness of Vision, “service providers on their ability to articulate logical statements convincingly about the market’s current and future direction, innovations, customer needs, and competitive forces, and on how well these correspond to Gartner’s position,” according to Gartner.

Gartner evaluation criteria puts “high” weighting on the following for Completeness of Vision: Market Understanding, Sales Strategy, Offering (Product) Strategy, Vertical/Industry Strategy, Innovation, and Geographic Strategy. “Medium” weighting is placed on Marketing Strategy and Business Model.

To read the full report, click here.

To learn more about managed IoT connectivity services, click here.

Gartner, Magic Quadrant for Managed IoT Connectivity Services, Worldwide; Pablo Arriandiago, Kameron Chao, Jon Dressel; March 11, 2025
Gartner, Voice of the Customer for Managed IoT Connectivity Services, Worldwide, Peer Contributors, 22 March 2024
Gartner, Magic Quadrant for 4G and 5G Private Mobile Network Services, Sylvain Fabre, Peter Liu, et al., 6 January 2025

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, PEER INSIGHTS and MAGIC QUADRANT are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

Verizon Communications Inc. (NYSE, Nasdaq: VZ) powers and empowers how its millions of customers live, work and play, delivering on their demand for mobility, reliable network connectivity and security. Headquartered in New York City, serving countries worldwide and nearly all of the Fortune 500, Verizon generated revenues of $134.8 billion in 2024. Verizon’s world-class team never stops innovating to meet customers where they are today and equip them for the needs of tomorrow. For more, visit verizon.com or find a retail location at verizon.com/stores.

VERIZON’S ONLINE MEDIA CENTER: News releases, stories, media contacts and other resources are available at verizon.com/news. News releases are also available through an RSS feed. To subscribe, visit www.verizon.com/about/rss-feeds/.

Media contact:
Matt Conte
[email protected]
(917) 848-3040



Workhorse to Begin Deliveries of Extended Wheelbase W56 Step Vans in Partnership with Revolv and Kingsburg Truck Center

Workhorse to begin deliveries of its new 208-inch extended wheelbase W56 step vans to a national provider of uniforms and workplace supplies

Revolv and Kingsburg Truck Center are facilitating the acquisition, upfitting, and deployment of the all-electric step vans

CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today announced it will begin delivering W56 step vans to a national provider of uniforms and workplace supplies in partnership with Revolv, a leader in full service fleet electrification solutions. The order, originally secured in 2024, has been adjusted to include 13 of Workhorse’s newly available 208-inch extended wheelbase W56 step vans, which Revolv will put into service for the customer in 2025.

The national provider of uniforms and workplace supplies has partnered with Revolv to acquire and deliver all of the all-electric W56 step vans. Revolv, known for providing comprehensive fleet electrification solutions, will support the customer in seamlessly integrating these vehicles into their operations, ensuring uptime performance and reliability. Kingsburg Truck Center, a certified Workhorse dealer, will provide a custom upfit tailored to the fleet’s operational needs. Based in California’s Central Valley, Kingsburg specializes in building, fabricating, and installing work truck upfits for a variety of industries, ensuring vehicles are optimized for maximum efficiency and performance.

“At Revolv, we help fleets make the shift to electric without economic or operational compromise, and Workhorse has proven to be a standout partner in the transition,” said Scott Davidson, CEO of Revolv. “The W56 delivers on both performance and reliability, but what truly sets Workhorse apart is their dedication to customer support. Their team works hand in hand with us and our fleet customers to ensure a seamless rollout, making electrification a practical reality. We’re excited to continue bringing Workhorse vehicles into our ecosystem and helping more fleets operate efficiently and deploy next-generation technology.”

The extended wheelbase W56 offers 1,200 cubic feet of cargo space, providing additional capacity for fleet operators managing high-volume delivery needs. With a range of up to 150 miles on a single charge and a payload capacity of up to approximately 10,000 pounds, the W56 is purpose-built for the demanding requirements of last-mile delivery.

“The W56 has continued to demonstrate its real-world performance and reliability, making it a strong fit for fleet operators transitioning to electric,” said Ryan Gaul, President, Commercial Vehicles at Workhorse. “This milestone not only reinforces our momentum in the commercial EV market but also showcases the confidence that fleet operators and electrification experts like Revolv have in the W56’s capabilities.”

Workhorse continues to scale production and deliveries of the W56, supporting customers in their transition to zero-tailpipe emission fleets. This latest milestone underscores the company’s commitment to providing reliable, high-performance commercial EVs that meet the needs of today’s fleet operators.

For more information about Workhorse and its full lineup of commercial EVs, visit www.workhorse.com.

About Workhorse Group Inc.

Workhorse Group Inc. (Nasdaq: WKHS) is a technology company focused on pioneering the transition to zero-emission commercial vehicles. Workhorse designs and builds its vehicles in the United States at the Workhorse Ranch in Union City, Indiana. The company’s best-in-class vehicles are designed for last-mile delivery, medium-duty operations, and a growing range of specialized applications. For more information, visit www.workhorse.com.

About Revolv

Revolv is helping national commercial fleets more quickly and confidently integrate electric vehicles into operations, without compromise. Through its innovative solution and approach, Revolv simplifies charging and vehicle deployments, enhances financial outcomes, and boosts operational performance, allowing fleets to focus on their core business. For more information, please visit www.revolv.us.

Forward-Looking Statements

The discussions in this press release contain forward-looking statements reflecting our current expectations that involve risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “expect,” “plan,” “believe,” “seek,” “estimate,” and similar expressions are intended to identify forward-looking statements and relate to future periods. These are statements that involve substantial risks and uncertainties, including our ability to timely deliver the W56 step vans applicable to the purchase order and conditions to delivery and acceptance thereof. Forward-looking statements are statements that are not historical facts and speak only as of the date hereof. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.

Media Contact:

Aaron Palash / Greg Klassen
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Investor Relations Contact:

Tom Colton and Greg Bradbury
Gateway Group
949-574-3860
[email protected]



Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

  • Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth.

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 19, 2025 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit” or the “Company”) today provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The Company has made significant progress with respect to confirmatory pre-clinical studies, clinical trial planning, formulation development, and intellectual property (IP) expansion to position its pipeline for continued success. These exciting developments underscore Conduit’s momentum and near-term potential.

Conduit has partnered with Charles River Laboratories Inc. to conduct preclinical studies evaluating its glucokinase inhibitors towards applications in autoimmune diseases, with an initial focus on lupus. The study aims to assess the impact of drug on disease progression in a well-established lupus model, using standard disease progression readouts, while also evaluating its effect on inflammatory markers and pro-inflammatory cytokine levels, with a focus on Treg immunoregulation. This study is expected to generate critical data on the therapeutic potential, informing future clinical development plans with results anticipated in Q2 2025, with a view to potentially increasing the probability of subsequent clinical trial success.

In parallel, Conduit continues to optimize the protocol for the design of its Phase II clinical trial for AZD1656. The trial will focus on two multisystem autoimmune diseases: systemic lupus erythematosus (SLE) with nephritis and ANCA-associated vasculitis (AAV). The current design is a single-center, double-blind, placebo-controlled study, designed to provide robust data on the safety, tolerability, and mechanistic effects of AZD1656. The Company will provide further updates on the finalization of the trial design and contracting for the study.

At its research and development facility at Cambridge Science Park, Conduit is enhancing its IP portfolio and optimize the formulation of its pipeline assets. In the laboratory, the Company is evaluating the assets licensed through the AstraZeneca partnership and other assets of critical interest. Significant progress has also been made in securing intellectual property (IP) protection for Conduit’s lead asset, AZD1656. Recent milestones include the grant of a composition-of-matter patent for the AZD1656 Cocrystals by the Japan Patent Office (JPO) and IP Australia, with pending applications at the USPTO and European Patent Office, and other global patent offices, expected to be approved early in the second quarter. In addition, Conduit is actively working to develop new solid forms of its key assets, including AZD1656, AZD5904 and AZD5658. These approvals and ongoing efforts are expected to strengthen Conduit’s IP portfolio and support its strategy of out-licensing and commercialization.

Through a strategic services agreement with Agility Life Sciences (“Agility”), a formulation development CDMO, Conduit is developing novel solid oral-dosage forms for its pipeline assets. Key activities include the development of proprietary solid forms for all autoimmune pipeline assets, protected by composition-of-matter IP, and collaboration with Agility to design enhanced oral dosage forms tailored to patient preferences and disease-specific needs. The development of proprietary forms of AZD1656, specifically tailored to unmet patient needs, are showing positive progress.

These efforts underscore Conduit’s commitment to advancing its pipeline and delivering innovative treatments for autoimmune disorders. The Company expects key results and critical milestones to be reached in the near term, positioning Conduit for exciting growth and development.

About Conduit Pharmaceuticals

Conduit is a multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit’s future results of operations and financial position, Conduit’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under “Risk Factors” therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.

Investors & Media:

[email protected]



Reliance Global Group Launches RELI Auto Leasing—Delivering ANY Vehicle to ANY Location in the United States

New Offering Provides Unmatched Convenience for Customers and Creates Additional Revenue Opportunities for RELI Exchange Agency Partners

LAKEWOOD, NJ, March 19, 2025 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: RELI) (“Reliance”, “we” or the “Company”) today announced the launch of RELI Auto Leasing, a groundbreaking service that enables RELI Exchange Agency Partners to seamlessly offer vehicle leasing to their clients while earning commissions on both the lease and the residual insurance policy. This innovative initiative reinforces the Company’s commitment to expanding revenue opportunities for agency partners while maintaining a strong focus on insurance services.

Home and auto policies are the core products of personal lines insurance. When clients seek a new vehicle, their insurance agent is often part of the discussion, advising on coverage options and facilitating policy transitions. After a vehicular accident, clients often look toward their insurance agent to discuss how to approach their replacement vehicle. Using our newly launched RELI Auto Leasing, insurance agents can now connect clients to vehicle leasing options without stepping outside their core business.

“One of the most important aspects of RELI Auto Leasing, is that our agency partners can earn more commissions without becoming trained in auto leasing. Instead, the agency partner seamlessly connects their clients with our trusted leasing partners from within their agent dashboard,” said Ezra Beyman, Chairman and CEO of Reliance Global Group. “This initiative is a game-changer for independent agents, enabling them to offer an added service without losing focus on their core insurance business. By incorporating auto leasing into client conversations, agents not only enhance their value proposition but also unlock new revenue streams that complement their existing insurance offerings. The leasing pricing is both competitive and convenient, making it an attractive choice for clients exploring vehicle lease options. Our agency partners have provided outstanding feedback on our advanced Insurtech white-labelled quoting engine and CRM, positioning RELI Exchange as the obvious choice as an insurance partner. We believe this additional path of revenue for our agency partners furthers our positive differentiator in the insurance industry.”

Clients benefit from a wide selection of vehicles, all available for delivery anywhere in the U.S., offering unmatched convenience. Whether seeking a new lease or upgrading a current vehicle, clients are now able to enjoy a streamlined process with guidance from a trusted insurance advisor. By bridging the gap between auto leasing and insurance, RELI Exchange empowers agency partners to deepen client relationships, foster long-term loyalty, and generate additional income—without added complexity.

Moshe Fishman, Director of Insurtech and Operations said, “RELI Auto Leasing is another win for our RELI Exchange Agency Partners, enabling them to strengthen their client relationships while earning additional commissions. When consumers are in the market for a new car, they often overlook how the make and model of their new car can impact their auto insurance premium. When clients include their RELI Exchange agency partner in the car buying process, they can project the effect that each car will have to their insurance premium. This proactive approach eliminates the surprise that happens all too often in the industry when someone gets a new car, only to learn later that their insurance premium increased far more than anticipated. We are proud that RELI Exchange agency partners are adding even more peace of mind to their clients.”

“Our vision for RELI Exchange has always been to maximize opportunities for our agency partners by providing a comprehensive suite of solutions aligned with their business model,” added Mr. Beyman. “RELI Auto Leasing is another step in our commitment to innovation—empowering independent agents to compete on a national scale through technology and strategic partnerships. As we continue expanding our ecosystem, we remain dedicated to delivering cutting-edge tools and services that drive success for our partners while enhancing the customer experience.”

About Reliance Global Group, Inc.

Reliance Global Group, Inc. (NASDAQ: RELI) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, while reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products. Further information about the Company can be found at https://www.relianceglobalgroup.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions and include statements such as the Company having built a best-in-class InsurTech platform, making RELI Exchange an even more compelling value proposition and further accelerating growth of the platform, rolling out several other services in the near future to RELI Exchange agency partners, building RELI Exchange into the largest agency partner network in the U.S., the Company moving in the right direction and the Company’s highly scalable business model driving significant shareholder value. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission and elsewhere ,and risks and uncertainties related to the Company’s ability to generate the revenue anticipated and the ability to build the RELI Exchange into the largest agency partner network in the U.S., and the other factors described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as the same may be updated from time to time. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, the Company’s Quarterly Reports on Form 10-Q, the Company’s Current Reports on Form 8-K and subsequent filings with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Contact:

Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: [email protected]